The impact of theCYP2D6gene polymorphism on the risk of pemphigoid-Reference-Cited by-同舟云学术

The impact of theCYP2D6gene polymorphism on the risk of pemphigoid

Published:2015-07-31 Issue:12 Volume:54 Page:1396-1401
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatol

Author:

Rychlik-Sych Mariola¹,Barańska Małgorzata¹,Wojtczak Anna¹,Skrętkowicz Jadwiga¹,Żebrowska Agnieszka²,Waszczykowska Elżbieta²

Affiliation:

1. Department of Pharmacogenetics; Medical University of Lodz; Lodz Poland

2. Department of Dermatology and Venereology; Medical University of Lodz; Lodz Poland

Funder

Uniwersytet Medyczny w Lodzi

Publisher

Wiley

Subject

Dermatology

Reference32 articles.

1. Characterization of N-acetyltransferase 1 and 2 polymorphism and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma;Mahid;BMC Med Genet,2007

2. Metabolizm leków;Rychlik-Sych;Farm Pol,2008

3. Clinical significance of some genetic polymorphisms of cytochrome P-450: family CYP1 and subfamilies CYP2A, CYP2B and CYP2C;Wojtczak;Pol Merkur Lekarski,2009

4. Clinical significance of some genetic polymorphisms of cytochrome P-450 subfamilies CYP2D, CYP2E and CYP3A - part II;Wojtczak;Pol Merkur Lekarski,2009

5. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality;Classen;JAMA,1997

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Humoral epitope spreading in autoimmune bullous diseases: An update;Translational Autoimmunity;2023

2. Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients’ Assessment;Clinical, Cosmetic and Investigational Dermatology;2022-04

3. The Immunogenetics of Autoimmune Blistering Diseases;The Immunogenetics of Dermatologic Diseases;2022

4. Pathogenesis-based treatments in bullous pemphigoid;Translational Autoimmunity;2022

5. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor–Induced Bullous Pemphigoid;Annals of Pharmacotherapy;2021-06-09